ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal' [Seeking Alpha]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Seeking Alpha
Follow Summary ImmunityBio received FDA approval for ANKTIVA plus BCG for BCG-unresponsive bladder cancer in April. The drug has a unique mechanism of action. Immunity's early launch progress of Anktiva shows promising market access initiatives, but financial concerns remain due to high R&D costs. Analysts project peak revenues of ~$900m by 2028 for Anktiva, although at present, Immunity's pricing of the drug is a little hard to understand. Anktiva is being evaluated in multiple clinical studies, including BCG naive bladder cancer, and lung cancer, in combo with checkpoint inhibitors. Immunity's billionaire founder Dr Patrick Soon Shiong believes the drug could become a long-term replacement for checkpoint inhibitors. If that thesis were proven correct, Immunity's valuation would skyrocket. ogichobanov Investment Overview - Understanding Immunity's Approved 'Vaccine' For Bladder Cancer I last covered ImmunityBio ( NASDAQ: IBRX ) in a note for Seeking Alpha back in l
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- Immunitybio Inc. (IBRX): Fast-Growing Penny Stock To Consider [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer Business Wire
- A Billionaire Saved A Nonprofit. Then Things Got Ugly [Forbes]Forbes
- ImmunityBio, Inc. (NASDAQ: IBRX) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.75. They now have a "neutral" rating on the stock.MarketBeat
- ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious [Seeking Alpha]Seeking Alpha
IBRX
Earnings
- 5/9/24 - Miss
IBRX
Sec Filings
- 8/12/24 - Form 10-Q
- 7/18/24 - Form 8-K
- IBRX's page on the SEC website